In the ongoing battle against cancer, medical researchers are constantly exploring innovative treatments that can effectively target and eliminate malignant cells while sparing healthy tissue. Among these emerging therapies, tumor-infiltrating lymphocyte (TIL) therapy stands out as a promising approach that harnesses the body's own immune system to combat cancer. Understanding Tumor-Infiltrating Lymphocytes TIL therapy revolves around a crucial component of the immune system: lymphocytes, specifically T cells. These specialized white blood cells play a pivotal role in identifying and destroying abnormal cells, including cancerous ones. However, in many cases, tumors manage to evade the immune system's surveillance mechanisms, allowing them to grow and spread unchecked. TIL therapy aims to overcome this evasion by extracting immune cells from a patient's tumor tissue, where T cells have already infiltrated the cancerous mass. These TILs are then isolated, expanded, and activated outside the body before being reintroduced into the patient. By bolstering the immune response with a concentrated dose of tumor-targeting T cells, this therapy seeks to tip the balance in favor of the immune system, enabling it to mount a more effective attack against the cancer. The Therapeutic Process The journey of TIL therapy begins with the surgical removal of a tumor specimen from the patient. From this tissue, TILs are isolated using specialized techniques in the laboratory. These extracted T cells are then cultured and expanded to increase their numbers dramatically, creating a robust army of immune cells primed for combat. Once a sufficient quantity of activated TILs has been generated, they are infused back into the patient's bloodstream. Due to specific molecular signals sent out by cancer cells, these engineered immune cells focus on the tumor site as they travel throughout the body. Upon reaching their destination, the TILs launch a multifaceted assault, directly attacking malignant cells and recruiting other components of the immune system to join the fight. The Promise of TIL Therapy One of the most compelling aspects of TIL therapy is its potential to achieve durable responses in patients with advanced or metastatic cancers. Clinical studies have shown promising results across a range of cancer types, including melanoma, cervical cancer, and gastrointestinal malignancies. In some cases, patients who have exhausted conventional treatment options have experienced remarkable tumor regression and prolonged survival following TIL therapy. Connect with CancerFax if you wish to avail of TIL therapy in China.

1. Tumor-infiltrating lymph E cells TlL S (Tumor Infltrating
Lymphocytes)
Immune cells for antitumor effects: CD4 + helper T cells, CD8 + cytotoxic
T cells, NK cells, M1 macrophages, dendritic cells, etc
* There are 540 clinical research projects in TILs worldwide
F o u r d i ff e r e n t t u m o r - i m m u n e m i c r o e n v i r o n m e n t s
Among them: type2 PDL 1 + / TIL + (Hot tumor *) tumor immune microenvironment
has a better response to immunotherapy
Data source ClinicalTrials.gov .～2023.10.10
Paijens , S.T., Vledder , A., de Bruyn , M.et al .Cell Mol Immunol 18, 842–859 (2021).
Solid tumors treatment — TILs

2. The deep remission of the tumor in the full recovery of immunity
Imaging assessment, swelling scale assessment, and immunity assessment
https://doi.org/10.1126/SC IENCE.AAA4967
Tumor type Cold tumor Hot tumor
The number of infiltrating
lymphocytes
low high
TCR, diversity low high
Immunotherapy response low high
Patient prognosis
inferiro
good
γδT low high
Cold Tumor - Hot Tumor

3. International TILs Research Progress - Tumor Types
The indications of TILs mainly focus on melanoma, non-small cell lung cancer, breast cancer, cervical cancer,
ovarian cancer, etc

4. FDA已授予TIL用于晚期宫颈癌的 BTD (breakthrough designation)
International TILs research progress - FDA breakthrough therapy recognition

5. International TILs Research Progress - Classic Scheme Design

6. Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.-C., Zheng,
Z., … Feldman, S. A. (2018). Immune recognition of somatic
mutations leading to complete durable regression in metastatic
breast cancer. Nature Medicine, 24(6), 724– 730.
Research progress of international TILs - Breast Cancer

7. International TILs research progress - non-small cell lung cancer

8. no. disease protocol ORR source
1
Unremovable or metastatic
melanoma
TIL 34.3%(n= 134) ASCO,2020
2 Metastatic cervical cancer TILs+PD-1 57.1% (8/14) Iovance
3
Non small cell lung cancer
PD-1 resistant metastatic non-
small cell lung cancer
TILs
TILs+PD-1
21.4%（ n=28 ）
37.5% （ 6/16 ）
Iovance
Nat Med.2021
4 Advanced head and neck cancer TILs+PD-1 38.9% (7/18) Iovance
6 Metastatic sarcoma TILs+PD-1 36.6% (n=60)
Journal of Immunology
Research.2020
International TILs Research Progress - Research Results
Wang, S., Sun, J., Chen, K. et al. BMC Med 19, 140 (2021).
3.1 6

9. Let's
Connect
With Us!
CANCERFAX
+1 213 789 56 55 (WhatsApp)
info@cancerfax.com
www.cancerfax.com